Over 200,000 new lung cancer patients are diagnosed every year, with over 150,000 deaths from the disease,
making it one of the most lethal cancers. (1) Non-small cell lung cancer (NSCLC) makes up 85% of lung cancer
patients in the US, with lung adenocarcinomas being the most common histological subtype of NSCLC. Lung
adenocarcinomas are frequently characterized by KRAS mutations, which appear to correlate with disease
aggressiveness. KRAS is also useful for predicting therapeutic response.(2)
KRAS mutations can arise at any point during cancer progression, and detection of mutations as they appear
is crucial to understanding the disease. Liquid biopsy of patient plasma is often used to understand disease
progression in NSCLC patients, as mutations present in solid tumors can often be detected in plasma samples
in low amounts. This non-invasive approach allows for more frequent sampling than traditional tissue biopsies
but requires the detection of very low-frequency alleles.
In this study, plasma from six NSCLC patients with known KRAS mutations was extracted by two different methods
and the digital PCR (dPCR) results were compared.
APPLICATION NOTE SKU 77XXX
Comments